Vicriviroc
Top View
- WO 2017/035230 Al 2 March 2017 (02.03.2017) P O P C T
- HIV-1 Entry Inhibition by Small-Molecule CCR5 Antagonists: a Combined Molecular Modeling and Mutant Study Using a High-Throughput Assay
- (12) Patent Application Publication (10) Pub. No.: US 2015/0322155A1 Zhao (43) Pub
- Anti-HIV Drugs: 25 Compounds Approved Within 25 Years After the Discovery of HIVଝ
- In Silico Study of Various Antiviral Drugs, Vitamins, and Natural Substances
- Planning for Long-Term Monitoring of Safety in Ccr5 Antagonist Development
- Selected Properties of Vicriviroc **In October 2005, Schering Plough
- Review Clinical Perspective on Antiretroviral Drug–Drug Interactions with the Non-Nucleoside Reverse Transcriptase Inhibitor Etravirine
- New Antiretroviral Therapies and Potential Drug Interactions in HIV
- Mechanisms of Ccr5 Agonist/Antagonist Inhibition of Hiv-1
- Kidney Disease in HIV: Moving Beyond HIV-Associated Nephropathy
- 33562549.Pdf
- Medical Management of HIV Infection Bartlett.Pdf
- HIV-1 Entry and Prospects for Protecting Against Infection
- TABLE I: Product and Corporate Developer / Protocol # and IND
- WO 2015/196116 Al 23 December 2015 (23.12.2015) P O P C T
- Maraviroc Therapy and CCR5 Genotype Laura Dean, MD1 Created: March 18, 2015
- Drug Interactions with New and Investigational Antiretrovirals